Research programme: brain injury therapeutics - Scythian Biosciences

Drug Profile

Research programme: brain injury therapeutics - Scythian Biosciences

Alternative Names: SCY001P

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scythian Biosciences
  • Class Cannabinoids; Neuroprotectants
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Fatty acid amide hydrolase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries

Most Recent Events

  • 30 Nov 2017 Preclinical trials in Brain injuries in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top